Role of aspirin and statin therapy in patients with cerebral cavernous malformations

[1]  Justin M. Moore,et al.  Symptomatic Hemorrhage From Cerebral Cavernous Malformations: Evidence from a Cohort Study. , 2019, World neurosurgery.

[2]  P. Mordasini,et al.  Antithrombotic medication and bleeding risk in patients with cerebral cavernous malformations: a cohort study. , 2019, Journal of neurosurgery.

[3]  L. Morrison,et al.  Familial Cerebral Cavernous Malformations , 2019, Stroke.

[4]  R. Sidman,et al.  Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease: A Review , 2019, JAMA neurology.

[5]  R. Shenkar,et al.  Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease , 2019, Stroke.

[6]  L. Morrison,et al.  Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. , 2018, Neurosurgery.

[7]  G. Gould,et al.  Cavernous Venous Malformation , 2018 .

[8]  S. Blackburn,et al.  Haemoglobin scavenging in intracranial bleeding: biology and clinical implications , 2018, Nature Reviews Neurology.

[9]  D. Kondziolka,et al.  Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel , 2017, Neurosurgery.

[10]  S. Retta,et al.  Oxidative stress and inflammation in cerebral cavernous malformation disease pathogenesis: Two sides of the same coin , 2016, The international journal of biochemistry & cell biology.

[11]  Robert D. Brown,et al.  Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data , 2016, The Lancet Neurology.

[12]  R. Scott,et al.  The natural history of cerebral cavernous malformations in children. , 2016, Journal of neurosurgery. Pediatrics.

[13]  A. Benz,et al.  Regulation of β1 integrin-Klf2-mediated angiogenesis by CCM proteins. , 2015, Developmental cell.

[14]  C. Sohn,et al.  A risk factor analysis of prospective symptomatic haemorrhage in adult patients with cerebral cavernous malformation , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  F. Tomasello,et al.  Sporadic Cerebral Cavernous Malformations: Report of Further Mutations of CCM Genes in 40 Italian Patients , 2013, BioMed research international.

[16]  I. Awad,et al.  Brainstem cavernous malformations: 1390 surgical cases from the literature. , 2013, World neurosurgery.

[17]  C. Tzourio,et al.  Antithrombotic Therapy and Bleeding Risk in a Prospective Cohort Study of Patients With Cerebral Cavernous Malformations , 2012, Stroke.

[18]  C. Warlow,et al.  Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study , 2012, The Lancet Neurology.

[19]  T. Christianson,et al.  Prospective hemorrhage risk of intracerebral cavernous malformations , 2012, Neurology.

[20]  A. Maat-Kievit,et al.  Cerebral cavernous malformations: from molecular pathogenesis to genetic counselling and clinical management , 2011, European Journal of Human Genetics.

[21]  N. Sciaky,et al.  Rho Kinase Inhibition Rescues the Endothelial Cell Cerebral Cavernous Malformation Phenotype* , 2010, The Journal of Biological Chemistry.

[22]  D. Rigamonti,et al.  Cavernous malformations: natural history, diagnosis and treatment , 2009, Nature Reviews Neurology.

[23]  Yoshito Tsushima,et al.  Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis , 2009, BMJ : British Medical Journal.

[24]  Christopher A. Jones,et al.  The Cerebral Cavernous Malformation signaling pathway promotes vascular integrity via Rho GTPases , 2009, Nature Medicine.

[25]  D. Hervé,et al.  From cavern-dwellers to cavernoma science: towards a new philosophy of cerebral cavernous malformations. , 2008, Stroke.

[26]  L. Morrison,et al.  Hemorrhage From Cavernous Malformations of the Brain: Definition and Reporting Standards , 2008, Stroke.

[27]  T. Haystead,et al.  Proteomic identification of the cerebral cavernous malformation signaling complex. , 2007, Journal of proteome research.

[28]  E. Tournier-Lasserve,et al.  Genetics of cavernous angiomas , 2007, The Lancet Neurology.

[29]  S. Sain,et al.  SPECTRUM OF GENOTYPE AND CLINICAL MANIFESTATIONS IN CEREBRAL CAVERNOUS MALFORMATIONS , 2006, Neurosurgery.

[30]  B. Crain,et al.  Ultrastructural and immunocytochemical evidence that an incompetent blood-brain barrier is related to the pathophysiology of cavernous malformations , 2001, Journal of neurology, neurosurgery, and psychiatry.

[31]  F. Giangaspero,et al.  Growth, subsequent bleeding, and de novo appearance of cerebral cavernous angiomas. , 1996, Neurosurgery.

[32]  John R. Robinson,et al.  Pathological heterogeneity of angiographically occult vascular malformations of the brain. , 1993, Neurosurgery.

[33]  John R. Robinson,et al.  Mixed vascular malformations of the brain: clinical and pathogenetic considerations. , 1993, Neurosurgery.

[34]  R. Shenkar,et al.  RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations , 2017, Stroke.

[35]  Robert D. Brown,et al.  Use of antithrombotic agents in patients with intracerebral cavernous malformations. , 2013, Journal of neurosurgery.

[36]  G. Johnson,et al.  Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling , 2013, Biological chemistry.

[37]  I. Awad,et al.  A comparison of the clinical profile of cavernous malformations with and without associated venous malformations. , 1999, Neurosurgery.